Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

Lupus

Volumn 9, Issue 6, 2000, Pages 401-405

  Blumenfeld, Z ^a,b   Shapiro, D ^a   Shteinberg, M ^a   Avivi, I ^a   Nahir, M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Cytotoxicity; Fertility; Gonadotoxicity; POF; SLE

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; LUTEINIZING HORMONE; PROGESTERONE; TRIPTORELIN;

ADULT; AMENORRHEA; ARTICLE; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOXICITY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; HUMAN; LYMPHOMA; NEPHROTIC SYNDROME; OVARY DISEASE; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSVAGINAL ECHOGRAPHY;

EID: 0033931644     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120300678828596     Document Type: Article

References (43)

1. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy - induced gonadotoxicity in young women. J Soc Gynecol Invest 1999; 6: 229-239.
2. Ataya K, Moghissi K. Chemotherapy induced premature ovarian failure: Medications and prevention. Steroids 1989; 54: 607-626.
3. Ataya KM, McKanna JA, Weintraub AM et al. Prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985; 45: 3651-3656.
4. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997; 29: 199-206.
5. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982; 9: 84-93.
6. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function. JAMA 1979; 242: 1877-1881.
7. Magrath I. Limiting therapy for limited childhood non-Hodgkin's lymphoma. N Engl J Med 1997; 337: 1304-1306.
8. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992; 28: 157-158.
9. Donadio JV, Holley KE, Wagoner RD et al. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972; 77: 829-835.
10. Decker JK, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: Results at 28 months. Ann Intern Med 1975; 83: 606-615.
11. Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
12. McCune WJ, Golbus J, Zeldes W et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe lupus erythematosus. N Engl J Med 1988; 318: 1423-1431.
13. Steinberg AD, Lindahl M, Gourley M et at. Approach to lupus nephritis based upon randomized trials. Proceedings of the 2nd International Conference on SLE, Singapore 20-30, November, 1989 pp 206-209.
14. Kahn MF. The treatment of lupus in the 1990's. Clin Exp Rheumatol 1990; 8(Suppl 5): 45-49.
15. De Vita S, Neri R, Bombardieri S. Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin Exp Rheumatol 1991; 9: 179-193.
16. Houssiau FA, D'cruz DP, Haga HJ, Hughes GRV. Short course of weekly low dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis. A premilinary study. Lupus 1991; 1: 31-35.
17. Balow JE, Austin HA, Tsokos GS et al. Lupus nephritis. Ann Intern Med 1987; 106: 79-94.
18. Klippel JH. Immune suppression in the treatment of SLE. In: Proceedings of the 2nd International Conference of SLE. Singapore 20-30, November, 1989 pp 200-202.
19. Warne GL, Fairley KF, Hobbs JB et al. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289: 1159-1162.
20. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982; 9: 84-94.
21. Kay HH, Mattison DR. How radiation and chemotherapy affect gonadal function. Contemp Obstet Gynecol 1985; 26: 109-127.
22. Padmanabhan N, Wang DY, Moore JW et al. Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Clin Oncol 1987; 23: 745-748.
23. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990; 1: 183-188.
24. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1274-1280.
25. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-837.
26. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-14.
27. Martin-Suarez I, D'Cruz D, Mansoor M et al. Immunosuppressive treatment in severe connective tissue diseases: effect of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-487.
28. D'Cruz D, Cuadrado MJ, Mujic F et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997; 15: 275-282.
29. Martin F, Lauwerys B, Lefebvre C et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-257.
30. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224-229.
31. Klippel JH, Austin HA IIIrd, Balow JE et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am 1987; 13: 47-56.
32. Bakchine H, Brauner R, Thibaud E et al. Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease. Arch Fr Pediatr 1986; 43: 611-616.
33. Petri M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7: 395-401.
34. Sanchez-Guerrero J, Liang MH, Karlson EW et al. Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430-433.
35. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1: 1132-1134.
36. Chapman RM, Sutcliffe S. The effects of chemotherapy and radiotherapy on fertility and their prevention. Recent Adv Clin Oncol 1986; 2: 239-251.
37. Krepart GV, Lotocki RJ. Chemotherapy during pregnancy. In: Allen HH, Nisker JA (eds). Cancer in Pregnancy, Therapeutic Guidelines. Futura: Mount Kisco, NY 1986, pp 69-88.
38. Ataya K, Rao LV, Laurence E, Kimmel R. Luteinizing hormone-releasng hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995; 52: 86-92.
39. Blumenfeld Z, Avivi I, Linn S et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620-1626.
40. Kreuser ED, Xirus N, Hetzel WD, Himpel A. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy of Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113: 260-266.
41. Rivkees SA, Crawford JD. The relationship of gonadal damage. JAMA 1988; 259: 2123-2125.
42. Blumenfeld Z, Ritter M, Shariki K, Haim N. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma-correlation with ovarian toxicity. Presented at the 44th annual meeting of the Society for Gynecologic Investigation, SanDiego, CA, 20-22 March, 1997. J Soc Gyn Investig 4(Suppl) & Am J Reprod Immunol 1998; 39: 33-40.
43. Blumenfeld Z, Ritter M, Shariki K, Haim N. Inhibin-A concentrations in sera of young women during and following chemotherapy for lymphoma-correlation with ovarian toxicity. Presented at the 44th annual meeting of the Society for Gynecologic Investigation, SanDiego, CA, 20-22 March, 1997. J Soc Gyn Investig 4(Suppl) & Am J Reprod Immunol 1998; 39: 33-40.